Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.

Basaran, GulDemirci, UmutYildiz, FatihCicin, IrfanAktas, Burak YasinOzturk, BanuGoksu, Sema Sezgin2024-06-122024-06-1220200732-183X1527-7755https://hdl.handle.net/20.500.14551/26767Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- MAY 29-31, 2020 -- ELECTR NETWORK[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keywords]Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.Conference Object3815Q1WOS:000560368304194